Hengrui Pharmaceutical Toluene Sulphate Remazene declared a third adaptive disorder

On December 2, according to the CDE official website Hengrui Pharmaceutical injection with toluene sulfonate remazene third new adaptive disease listing application was accepted, according to the drug conducted in the domestic clinical trials, the author speculated that the declared new adaptive is general anaesthetic.
toluene sulfonate is a salt-modified compound of rematrophon.
designed by GSK and developed by PaionAG, a short-acting GABAa-subject agonist that is fast-acting, fails quickly, has virtually no inhibition of the respiratory system and cardiovascular system, and is metabolized by tissue esterase, metabolites are inactive, and can be antagonized by fluoxetamolone, which has a more obvious advantage over traditional use of midazolam and propofol.
December 2019, toluene sulfonate was first approved by the NMPA for gastroscopy sedatives, a product called Ripinen.
June 2020, the drug was approved for colonoscopy to check for sedation.
addition, according to the CDE drug clinical trial registration and information company platform toluene sulfonate rimazoleon has also been developed for general anaesthetic, bronchopneotic sedatives.
addition, applications for clinical trials of toluene sulfonate for sedation and mechanical calming of the ICU during non-intestor anaesthetic surgery, during surgery and other operations have also been tacitly approved.
the progress of the above-mentioned adaptation-related clinical trials, the author speculates that the declared new adaptation is general anaesthetic.
Mention of Ripinen, it has to be said that the human-fu pharmaceutical industry's benzodialyc acid remathorum, the drug is a product obtained by human-blessed pharmaceutical industry in 2012 with 3 million yuan and subsequent sales share agreement, but the progress of the drug is obviously a little backward, just in July this year was approved by the NMPA for colonoscopy treatment when calming down, the product is called Rema.
there is a great deal of re-existing adaptations between the two drugs, which have also been developed for general anaesthetic induction and maintenance, tracheal sedation, and are expected to be the start of a fierce market battle.
according to insight database, the latest winning bid of Ruipening (36mg/branch) is 266 yuan, and the scrap list price of Rema (25mg/branch) in Shandong is 31.98 yuan, which seems to be a bit of a price war trend.
when it comes to narcotic drugs, we have to say that Hengrui Pharmaceuticals and Renfu Pharmaceuticals, two companies, are the domestic anaesthetic industry leader.
Among them, the anesthetic products of the human medicine industry are fentanyl as the core, the main products includeacid fentanyl injection,acid fentanyl injection, injectable hydrochloric acid ryfentanyl and hydrochloric acid afentanyl injection, of which saffenitinie and afentanyl are the exclusive products of the pharmaceutical industry, in addition to the pharmaceutical industry has hydro morphine this exclusive product.
fentanine is a commonly used analgesic drug, can also be used as an anesthetic auxiliary drugs and narcotic drugs, it is known that the pharmaceutical industry in the domestic fentanine market share of up to 80%.
And Hengrui Pharmaceutical's anaesthetic products include right metomycin, hexafluorane, bhutolphine, shun atroclicumamide and toluazolen, of which only buprenorphine is the exclusive product of Hengrui Pharmaceuticals.
Right metomye is used for sedation in trachea intination and mechanical anaesthetic in surgical patients, hexafluorane is the most commonly used inhalation anesthetic in the clinic, according to Minet data Hengrui Pharmaceuticals in these two product areas riding dust, 2018 market share of more than 50% and 80%, respectively.
In addition, Human Fu Pharmaceuticals and Hengrui Pharmaceuticals also have the same anaesthetic product under study, namely M6G (morphine-6-glucosides), the active metabolite of morphine in the body, belongs to the opioid analgesics, can be used for moderate to severe pain treatment.
M6G analgesics are more active, last longer and have better tolerance than morphine preparations, which can effectively improve adverse reactions such as nausea, vomiting and respiratory suppression.
, according to insight database, the phase 1 clinical trial of Human Fu Pharmaceuticals M6G has been completed, while the Phase 1 clinical trial of Hengrui Pharmaceuticals M6G has not been completed.
today, Hengrui Pharmaceuticals is a leader in the field of Rema Lun Fu Pharmaceuticals, but from their respective anaesthetic product pipeline, the future of domestic anesthesiology products enterprise pattern is not yet conceived.
References: s1.
CDE's official website, Insight Database